Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.
Fiche publication
Date publication
mai 2020
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel
Tous les auteurs :
Janoray G, Pointreau Y, Alfonsi M, Sire C, Geoffrois L, de Raucourt D, Bardet E, Calais MH, Garaud P, Calais G
Lien Pubmed
Résumé
In Europe, induction chemotherapy (ICT) followed by radiotherapy is preferred to conventional chemoradiotherapy to avoid total laryngectomy in patients with laryngeal/hypopharyngeal cancer. In comparison with conventional radiotherapy, bioradiotherapy with cetuximab significantly improves locoregional control rates (LCRs) and overall survival (OS) without any increase in unmanageable toxicity.
Mots clés
Induction chemotherapy, Laryngo-oesophageal dysfunction-free survival, Larynx preservation, Quality of life, Radiation therapy
Référence
Eur. J. Cancer. 2020 May 23;133:86-93